This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
UNVACCINATED PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES HAVE HETEROGENEOUS AND UNRELATED RISKS OF COVID INFECTION AND POOR OUTCOME (preprint)
EuropePMC; 2022.
Preprint
in English
| EuropePMC | ID: ppcovidwho-337862
ABSTRACT
Background:
The impact of the severe acute respiratory syndrome Coronavirus 2 disease (COVID-19) pandemic on people with systemic autoimmune rheumatic diseases (SARDs) is not fully established. It is unclear whether SARDs are an independent risk factor for infection and poor outcomes.Methods:
Incidence and 30-day outcomes of COVID-19 infection were retrospectively evaluated in 40,490 SARD patients in the Lazio Italian Region and compared to the general population as incidence rate ratio adjusted for demographics and comorbidities (adjIRR). SARD diagnosis and comorbidities were derived from medical administrative records using the Chronic Related Group classification system. Data on COVID-19 infection were derived from a dedicated regional digital network.Results:
The COVID-19 infection risk was increased in patients with Psoriatic Arthritis (adjIRR=1.21, 95% CI 1.10-1.33) and Undifferentiated Connective Tissue Disease (adjIRR=1.26, 95% CI 1.03-1.54). The hospitalization risk was higher in patients with Axial Spondylarthritis (adjIRR=2.16, 95% CI 1.45-3.22), and Systemic Vasculitis (adjIRR=1.81, 95% CI 1.07-3.06) while intensive care unit admission risk was higher in Systemic Erythematosus Lupus (adjIRR=3.67, 95% CI 1.52-8.83) and primary Sjögren Syndrome (adjIRR=4.13, 95% CI 1.71-9.96) patients. Increased mortality was reported in patients with Rheumatoid Arthritis (adjIRR=1.50, 95% CI 1.04-2.17), Systemic Erythematosus Lupus (adjIRR=2.67, 95% CI 1.10-6.44), primary Sjögren Syndrome (adjIRR=2.51, 95% CI 1.12-5.62), and Scleroderma (adjIRR=4.60, 95% CI 2.06-10.29).Conclusions:
Each SARDs presents a peculiar pattern in terms of increased risk of COVID-19 incidence, hospitalization, intensive care unit admission, and death, that is not linked to the immunosuppressive behaviour of the disease.
Full text:
Available
Collection:
Preprints
Database:
EuropePMC
Type of study:
Etiology study
/
Risk factors
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS